Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Multicenter, Investigator-blinded, Randomized, Comparative Study Estimate Safety, Tolerability, Efficacy of NXL104/Ceftazidime vs. Comparator Followed Appropriate Oral Therapy Treatment Complicated UTI Hosp Adults

NCT00690378 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00690378
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00690378 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Multicenter, Investigator-blinded, Randomized, Comparative Study Estimate Safety, Tolerability, Efficacy of NXL104/Ceftazidime vs. Comparator Followed Appropriate Oral Therapy Treatment Complicated UTI Hosp Adults
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2008
Completion date
July 31, 2010
Enrollment
137 (actual)
Sites
59

Conditions

As the registry lists them; a condition with its own page is linked.

complicated urinary tract infection